Movatterモバイル変換

[0]ホーム
URL:

SG10201806787VA - Modulators of complement factor b - Google Patents

Modulators of complement factor b

Info

Publication number
SG10201806787VA
SG10201806787VASG10201806787VASG10201806787VASG10201806787VASG 10201806787V ASG10201806787V ASG 10201806787VASG 10201806787V ASG10201806787V ASG 10201806787VASG 10201806787V ASG10201806787V ASG 10201806787VASG 10201806787V ASG10201806787V ASG 10201806787VA
Authority
SG
Singapore
Prior art keywords
modulators
complement factor
complement
factor
cfb
Prior art date
Application number
SG10201806787VA
Inventor
Tamar Grossman
Michael Mccaleb
Andrew Watt
Susan Freier
Original Assignee
Ionis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ionis Pharmaceuticals IncfiledCriticalIonis Pharmaceuticals Inc
Publication of SG10201806787VApublicationCriticalpatent/SG10201806787VA/en

Links

Classifications

Landscapes

Abstract

MODULATORS OF COMPLEMENT FACTOR B The embodiments methods, and tions treating, or ameliorating disease with of complement pathway administering a Complement Factor B (CFB) specific inhibitor to a subject. No Figure
SG10201806787VA2013-09-132014-09-12Modulators of complement factor bSG10201806787VA (en)

Applications Claiming Priority (1)

Application NumberPriority DateFiling DateTitle
US201361877624P2013-09-132013-09-13

Publications (1)

Publication NumberPublication Date
SG10201806787VAtrue SG10201806787VA (en)2018-09-27

Family

ID=52666522

Family Applications (2)

Application NumberTitlePriority DateFiling Date
SG10201806787VASG10201806787VA (en)2013-09-132014-09-12Modulators of complement factor b
SG11201601445XASG11201601445XA (en)2013-09-132014-09-12Modulators of complement factor b

Family Applications After (1)

Application NumberTitlePriority DateFiling Date
SG11201601445XASG11201601445XA (en)2013-09-132014-09-12Modulators of complement factor b

Country Status (32)

CountryLink
US (5)US20160222389A1 (en)
EP (2)EP3043827B1 (en)
JP (3)JP6666250B2 (en)
KR (1)KR102381790B1 (en)
CN (2)CN112359042A (en)
AU (2)AU2014318580B2 (en)
BR (1)BR112016004671B1 (en)
CA (1)CA2921842A1 (en)
CL (2)CL2016000606A1 (en)
CR (1)CR20160170A (en)
DK (1)DK3043827T3 (en)
DO (1)DOP2016000063A (en)
EA (1)EA035433B1 (en)
ES (1)ES2745758T3 (en)
HR (1)HRP20191600T1 (en)
HU (1)HUE045109T2 (en)
IL (1)IL244095A0 (en)
LT (1)LT3043827T (en)
MA (1)MA38959A1 (en)
MX (2)MX371518B (en)
MY (1)MY181251A (en)
PE (2)PE20160500A1 (en)
PH (1)PH12016500443A1 (en)
PL (1)PL3043827T3 (en)
PT (1)PT3043827T (en)
RS (1)RS59252B1 (en)
RU (1)RU2662967C2 (en)
SG (2)SG10201806787VA (en)
SI (1)SI3043827T1 (en)
UA (1)UA119046C2 (en)
WO (1)WO2015038939A2 (en)
ZA (1)ZA201601236B (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
ATE540118T1 (en)2006-10-182012-01-15Isis Pharmaceuticals Inc ANTISENSE COMPOUNDS
MX340397B (en)2009-09-112016-07-07Ionis Pharmaceuticals IncModulation of huntingtin expression.
US10017764B2 (en)2011-02-082018-07-10Ionis Pharmaceuticals, Inc.Oligomeric compounds comprising bicyclic nucleotides and uses thereof
BR112015027321A8 (en)2013-05-012018-01-02Isis Pharmaceuticals Inc COMPOUNDS AND COMPOSITIONS FOR MODULING APOLIPOPROTEIN(A) EXPRESSION AND THEIR USES
SG10201806787VA (en)*2013-09-132018-09-27Ionis Pharmaceuticals IncModulators of complement factor b
EA201691215A1 (en)*2013-12-122016-11-30Элнилэм Фармасьютикалз, Инк. COMPOSITIONS ON THE BASIS OF IRNA TO THE COMPONENT OF THE COMPLEX AND METHODS OF THEIR APPLICATION
KR102369736B1 (en)2014-05-012022-03-02아이오니스 파마수티컬즈, 인코포레이티드Compositions and methods for modulating complement factor b expression
WO2017135397A1 (en)*2016-02-052017-08-10協和発酵キリン株式会社Antisense oligonucleotide for suppressing expression of complement b factor
KR20190036520A (en)2016-06-272019-04-04아칠리온 파르마세우티칼스 인코포레이티드 Quinazoline and indole compounds for the treatment of medical disorders
AU2017368050A1 (en)2016-11-292019-06-20Puretech Lyt, Inc.Exosomes for delivery of therapeutic agents
WO2018117253A1 (en)*2016-12-232018-06-28協和発酵キリン株式会社Nucleic acid inhibiting expression of complement factor b
WO2019027015A1 (en)*2017-08-022019-02-07協和発酵キリン株式会社Nucleic acid complex
WO2019089922A1 (en)2017-11-012019-05-09Alnylam Pharmaceuticals, Inc.Complement component c3 irna compositions and methods of use thereof
WO2020109343A1 (en)2018-11-292020-06-04F. Hoffmann-La Roche AgCombination therapy for treatment of macular degeneration
KR20220084399A (en)2019-10-222022-06-21알닐람 파마슈티칼스 인코포레이티드 Complement component C3 iRNA compositions and methods of use thereof
BR112022021136A2 (en)*2020-04-302022-11-29Alnylam Pharmaceuticals Inc COMPLEMENT FACTOR B IRNA COMPOSITIONS (CFB) AND METHODS OF USE THEREOF
WO2022028507A1 (en)2020-08-072022-02-10上海美悦生物科技发展有限公司Heterocyclic compound, preparation method therefor and use thereof
MX2023001517A (en)2020-08-072023-03-06Shanghai Meiyue Biotech Dev Co LtdComplement factor b inhibitor, and pharmaceutical composition thereof, preparation method therefor and use thereof.
KR20240035563A (en)*2021-07-172024-03-15서나오믹스, 인크. Products and Compositions
AU2022336157A1 (en)2021-09-022024-03-14Silence Therapeutics GmbhNucleic acids for inhibiting expression of complement factor b (cfb) in a cell
CA3234636A1 (en)2021-10-292023-05-04Alnylam Pharmaceuticals, Inc.Complement factor b (cfb) irna compositions and methods of use thereof
US20250075209A1 (en)*2021-12-272025-03-06Apellis Pharmaceuticals, Inc.Rnas for complement inhibition
TWI843416B (en)2022-01-262024-05-21大陸商上海美悦生物科技發展有限公司Salt form and crystal form of complement factor b inhibitor and preparation method and use thereof
WO2024051849A1 (en)2022-09-102024-03-14Jiangsu Hansoh Pharmaceutical Group Co., Ltd.2-substituted piperidine derivatives, preparation methods and medicinal uses thereof
CN120379677A (en)*2022-11-022025-07-25Ionis制药公司Methods for modulating complement factor B expression
WO2024245424A1 (en)*2023-06-022024-12-05维亚臻生物技术（苏州）有限公司Double-stranded nucleotide compound for immune disease and use thereof
TW202500169A (en)*2023-06-282025-01-01大陸商上海舶望製藥有限公司Compositions and methods for inhibiting expression of complement factor b (cfb)
WO2025002401A1 (en)*2023-06-282025-01-02百奥赛图(北京)医药科技股份有限公司Cfb gene modified non-human animal
WO2025122669A1 (en)*2023-12-052025-06-12Regeneron Pharmaceuticals, Inc.Non-human animals having a humanized complement factor b gene

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US5118800A (en)1983-12-201992-06-02California Institute Of TechnologyOligonucleotides possessing a primary amino group in the terminal nucleotide
FR2567892B1 (en)1984-07-191989-02-17Centre Nat Rech Scient NOVEL OLIGONUCLEOTIDES, THEIR PREPARATION PROCESS AND THEIR APPLICATIONS AS MEDIATORS IN DEVELOPING THE EFFECTS OF INTERFERONS
US5166315A (en)1989-12-201992-11-24Anti-Gene Development GroupSequence-specific binding polymers for duplex nucleic acids
US5506337A (en)1985-03-151996-04-09Antivirals Inc.Morpholino-subunit combinatorial library and method
US5185444A (en)1985-03-151993-02-09Anti-Gene Deveopment GroupUncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US5034506A (en)1985-03-151991-07-23Anti-Gene Development GroupUncharged morpholino-based polymers having achiral intersubunit linkages
US5591722A (en)1989-09-151997-01-07Southern Research Institute2'-deoxy-4'-thioribonucleosides and their antiviral activity
DK0497875T3 (en)1989-10-242000-07-03Gilead Sciences Inc 2'-modified oligonucleotides
US5670633A (en)1990-01-111997-09-23Isis Pharmaceuticals, Inc.Sugar modified oligonucleotides that detect and modulate gene expression
US5646265A (en)1990-01-111997-07-08Isis Pharmceuticals, Inc.Process for the preparation of 2'-O-alkyl purine phosphoramidites
GB9009980D0 (en)1990-05-031990-06-27Amersham Int PlcPhosphoramidite derivatives,their preparation and the use thereof in the incorporation of reporter groups on synthetic oligonucleotides
DE69032425T2 (en)1990-05-111998-11-26Microprobe Corp., Bothell, Wash. Immersion test strips for nucleic acid hybridization assays and methods for covalently immobilizing oligonucleotides
EP0538194B1 (en)1991-10-171997-06-04Novartis AGBicyclic nucleosides, oligonucleotides, their method of preparation and intermediates therein
US5359044A (en)1991-12-131994-10-25Isis PharmaceuticalsCyclobutyl oligonucleotide surrogates
FR2687679B1 (en)1992-02-051994-10-28Centre Nat Rech Scient OLIGOTHIONUCLEOTIDES.
EP0577558A2 (en)1992-07-011994-01-05Ciba-Geigy AgCarbocyclic nucleosides having bicyclic rings, oligonucleotides therefrom, process for their preparation, their use and intermediates
JPH08504559A (en)1992-12-141996-05-14ハネウエル・インコーポレーテッド Motor system with individually controlled redundant windings
DE69404289T2 (en)1993-03-301998-02-19Sanofi Sa ACYCLIC NUCLEOSIDE ANALOGS AND THEIR OLIGONUCLEOTIDE SEQUENCES
US5446137B1 (en)1993-12-091998-10-06Behringwerke AgOligonucleotides containing 4'-substituted nucleotides
US5519134A (en)1994-01-111996-05-21Isis Pharmaceuticals, Inc.Pyrrolidine-containing monomers and oligomers
US5627053A (en)1994-03-291997-05-06Ribozyme Pharmaceuticals, Inc.2'deoxy-2'-alkylnucleotide containing nucleic acid
US5597909A (en)1994-08-251997-01-28Chiron CorporationPolynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use
US6770748B2 (en)1997-03-072004-08-03Takeshi ImanishiBicyclonucleoside and oligonucleotide analogue
JP3756313B2 (en)1997-03-072006-03-15武 今西 Novel bicyclonucleosides and oligonucleotide analogues
ATE293123T1 (en)1997-09-122005-04-15Exiqon As BI- AND TRI-CYCLIC - NUCLEOSIDE, NUCLEOTIDE AND OLIGONUCLEOTIDE ANALOGS
US6794499B2 (en)1997-09-122004-09-21Exiqon A/SOligonucleotide analogues
US6043352A (en)1998-08-072000-03-28Isis Pharmaceuticals, Inc.2'-O-Dimethylaminoethyloxyethyl-modified oligonucleotides
AU1705100A (en)*1998-10-092000-05-01Musc Foundation For Research DevelopmentBlocking factor b to treat complement-mediated immune disease
CA2370628A1 (en)1999-04-212000-10-26American Home Products CorporationMethods and compositions for inhibiting the function of polynucleotide sequences
US7053207B2 (en)1999-05-042006-05-30Exiqon A/SL-ribo-LNA analogues
US6525191B1 (en)1999-05-112003-02-25Kanda S. RamasamyConformationally constrained L-nucleosides
EP1244667B1 (en)1999-12-302006-04-05K.U. Leuven Research & DevelopmentCyclohexene nucleic acids
JP2005504020A (en)2001-07-032005-02-10アイシス・ファーマシューティカルス・インコーポレーテッド Nuclease resistant chimeric oligonucleotide
US6964950B2 (en)*2001-07-252005-11-15Isis Pharmaceuticals, Inc.Antisense modulation of C-reactive protein expression
AU2003274973A1 (en)*2002-09-132004-04-30Invitrogen CorporationThermostable reverse transcriptases and uses thereof
AU2003291753B2 (en)2002-11-052010-07-08Isis Pharmaceuticals, Inc.Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
AU2003291755A1 (en)2002-11-052004-06-07Isis Pharmaceuticals, Inc.Oligomers comprising modified bases for binding cytosine and uracil or thymine and their use
EP2305812A3 (en)*2002-11-142012-06-06Dharmacon, Inc.Fuctional and hyperfunctional sirna
US6673661B1 (en)2002-12-202004-01-06Taiwan Semiconductor Manufacturing Co., Ltd.Self-aligned method for forming dual gate thin film transistor (TFT) device
WO2004103288A2 (en)2003-05-132004-12-02New York Society For The Ruptured And Crippled Maintaining The Hospital For Special SurgeryMethod of preventing recurrent miscarriages
ATE555118T1 (en)2003-08-282012-05-15Takeshi Imanishi NEW SYNTHETIC NUCLEIC ACIDS OF THE CROSS-LINKED N-O BOND TYPE
EP1677822B1 (en)2003-09-182014-04-23Isis Pharmaceuticals, Inc.4'-thionucleosides and oligomeric compounds
US7959919B2 (en)*2003-11-192011-06-14Novelmed Therapeutics, Inc.Method of inhibiting factor B-mediated complement activation
BRPI0506629A (en)*2004-02-102007-05-02Univ Colorado factor b inhibition, the alternative complement system pathway and related methods
KR20070085113A (en)*2004-05-112007-08-27가부시키가이샤 알파젠 Polynucleotides causing RNA interference, and gene expression inhibition method using the same
CA2568735A1 (en)2004-06-032005-12-22Isis Pharmaceuticals, Inc.Double strand compositions comprising differentially modified strands for use in gene modulation
EP2397563A3 (en)*2004-09-172012-07-18Isis Pharmaceuticals, Inc.Enhanced antisense oligonucleotides
EP1812569A2 (en)2004-11-082007-08-01K.U. Leuven Research and DevelopmentModified nucleosides for rna interference
GB0521716D0 (en)*2005-10-252005-11-30Genomica SauModulation of 11beta-hydroxysteriod dehydrogenase 1 expression for the treatment of ocular diseases
ES2516815T3 (en)2006-01-272014-10-31Isis Pharmaceuticals, Inc. Analogs of bicyclic nucleic acids modified at position 6
CN101490074B (en)2006-05-112013-06-26Isis制药公司 5'-Modified Bicyclic Nucleic Acid Analogs
US8252755B2 (en)*2006-09-222012-08-28Dharmacon, Inc.Duplex oligonucleotide complexes and methods for gene silencing by RNA interference
CN101589143A (en)*2006-11-272009-11-25Isis药物公司Methods for treating hypercholesterolemia
WO2008101157A1 (en)2007-02-152008-08-21Isis Pharmaceuticals, Inc.5'-substituted-2'-f modified nucleosides and oligomeric compounds prepared therefrom
WO2008106644A2 (en)*2007-03-012008-09-04Advanced Vision Therapies, Inc.Treatment of diseases characterized by inflammation
ES2388590T3 (en)2007-05-302012-10-16Isis Pharmaceuticals, Inc. Analogs of bicyclic nucleic acids with N-substituted aminomethylene bridge.
WO2008154401A2 (en)2007-06-082008-12-18Isis Pharmaceuticals, Inc.Carbocyclic bicyclic nucleic acid analogs
EP2176280B2 (en)2007-07-052015-06-24Isis Pharmaceuticals, Inc.6-disubstituted bicyclic nucleic acid analogs
PL2320925T3 (en)*2008-07-102016-06-30Regenesance B VComplement antagonists and uses thereof
DK2361256T3 (en)2008-09-242013-07-01Isis Pharmaceuticals Inc Cyclohexenyl-nucleic acid analogues
EP2601204B1 (en)2010-04-282016-09-07Ionis Pharmaceuticals, Inc.Modified nucleosides and oligomeric compounds prepared therefrom
US20130237585A1 (en)*2010-07-192013-09-12University Of RochesterModulation of dystrophia myotonica-protein kinase (dmpk) expression
CA2832972C (en)*2011-04-132019-04-30Isis Pharmaceuticals, Inc.Antisense modulation of ptp1b expression
SG10201806787VA (en)2013-09-132018-09-27Ionis Pharmaceuticals IncModulators of complement factor b
KR102369736B1 (en)*2014-05-012022-03-02아이오니스 파마수티컬즈, 인코포레이티드Compositions and methods for modulating complement factor b expression

Also Published As

Publication numberPublication date
AU2020201763A1 (en)2020-04-02
JP6666250B2 (en)2020-03-13
JP7158363B2 (en)2022-10-21
KR20160054595A (en)2016-05-16
MY181251A (en)2020-12-21
HUE045109T2 (en)2019-12-30
CN105744959A (en)2016-07-06
KR102381790B1 (en)2022-03-31
RU2016113763A (en)2017-10-16
RS59252B1 (en)2019-10-31
MX2016003263A (en)2016-12-08
MX2020001258A (en)2020-03-20
ES2745758T3 (en)2020-03-03
RU2662967C2 (en)2018-07-31
JP2020036600A (en)2020-03-12
SI3043827T1 (en)2019-08-30
CR20160170A (en)2016-07-15
PH12016500443A1 (en)2016-05-16
EP3603677A1 (en)2020-02-05
EP3043827A4 (en)2017-05-24
UA119046C2 (en)2019-04-25
US11926830B2 (en)2024-03-12
MX371518B (en)2020-01-31
SG11201601445XA (en)2016-03-30
EP3043827A2 (en)2016-07-20
CL2018002334A1 (en)2018-12-14
IL244095A0 (en)2016-04-21
EP3043827B1 (en)2019-07-03
AU2014318580B2 (en)2019-12-12
DK3043827T3 (en)2019-08-26
US20160222389A1 (en)2016-08-04
ZA201601236B (en)2017-05-31
PL3043827T3 (en)2020-03-31
CA2921842A1 (en)2015-03-19
US20190048351A1 (en)2019-02-14
MA38959A1 (en)2017-08-31
US20220243209A1 (en)2022-08-04
WO2015038939A2 (en)2015-03-19
LT3043827T (en)2019-08-12
JP7297112B2 (en)2023-06-23
CN105744959B (en)2020-12-01
HK1225638A1 (en)2017-09-15
JP2016533765A (en)2016-11-04
BR112016004671B1 (en)2020-12-29
CL2016000606A1 (en)2017-02-17
PT3043827T (en)2019-09-26
US20200149047A1 (en)2020-05-14
EA035433B1 (en)2020-06-15
EA201690582A1 (en)2016-07-29
AU2014318580A1 (en)2016-03-03
CN112359042A (en)2021-02-12
US20240247268A1 (en)2024-07-25
HRP20191600T1 (en)2019-11-29
PE20190354A1 (en)2019-03-07
PE20160500A1 (en)2016-05-21
JP2022058784A (en)2022-04-12
DOP2016000063A (en)2016-06-01
WO2015038939A3 (en)2015-07-02

Similar Documents

PublicationPublication DateTitle
SG10201806787VA (en)Modulators of complement factor b
PH12020551397A1 (en)Cot modulators and methods of use thereof
SG10201809953QA (en)Compositions and methods for modulating complement factor b expression
MX2018003472A (en)Modulators of kras expression.
CL2016000354A1 (en) Modulation of tumor immunity
JO3343B1 (en)Novel5-aminotetrahydroquinoline-2-carboxylic acids and their use
NI201500150A (en) CANCER TREATMENT WITH DIHYDROPIRAZINE-PIRAZINES × Provided in this method
CA2908742C (en)Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer
PH12016501965A1 (en)S1p modulator immediate release dosage regimen
GT201200345A (en) HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR THERAPY APPLICATION
CL2016001428A1 (en) Use of a composition with cognitive exercises useful for the prevention or treatment of delayed cognitive development in children.
PH12017500084A1 (en)Vitamin b2 and its use
IN2014KN01772A (en)
MY184721A (en)Use of odiparcil in the treatment of a mucopolysaccharidosis
UA87629U (en)Method for preventing and correcting difficulties in adapting foreign students to new conditions of life and study load
CR20190329A (en)MODULATORS OF COMPLEMENT FACTOR Bi
UA74770U (en)method for treating patients with chronic hepatobiliary pathology on the background of enhanced fatigue syndrome
UY34233A (en) ANTITUMORAL COMBINATION THAT INCLUDES OMBRABULINA AND CETUXIMAB, ASSOCIATED WITH RADIOTHERAPY
UA84204U (en)Method for immunocorrection of patients with chickenpox and immunodeficient state
UA84195U (en)Method for treating influenza in adult patients
UA89118U (en)Method for treating antiphospholipid syndrome
UA89119U (en)Method for treating antiphospholipid syndrome
[8]ページ先頭
©2009-2025 Movatter.jp